BioSpace News Archive

Arbor Biotechnologies, a biotechnology company discovering and developing the next generation of genetic medicines, today announced that its Chief Executive Officer, Devyn Smith, Ph.D., has been elected as the Chairman of the Alliance for Regenerative Medicine (ARM), the leading international advocacy organization dedicated to realizing the promise of regenerative medicines and advanced therapies.

Bolt Threads today announced a multi-project collaboration to increase the production efficiency and performance of Bolt’s current portfolio as well as expand it by developing novel proteins for biomaterials.

Harbour BioMed announced that, it has successfully completed the dosing of first patient in the global phase I trial of B7H4x4-1BB bispecific antibody HBM7008 in the United States.

BrainStorm Cell Therapeutics Inc. announced that a scientific abstract titled ‘NurOwn Phase 2 Clinical Trial in Progressive MS: Effects on CSF Neuroprotective Biomarkers’ will be presented at the 38th Congress of the European Committee for Treatment and Research in Multiple Sclerosis, being held from October 26-28th in Amsterdam, NL.

Vaxart, Inc. (NASDAQ: VXRT) today announced it will provide a business update and report financial results for the third quarter ended September 30, 2022 after the market close on Tuesday, November 8, 2022.

CorMedix Inc. today announced that an abstract has been accepted for presentation at the American Society of Nephrology (ASN) annual meeting being held in Orlando, Florida, November 3 – 6.

Nanomix Corporation today announced a new distribution agreement with Diaclinic SpA (“Diaclinic”), a medical distributor headquartered in Santiago, Chile.

Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, will report financial results for the third quarter 2022 after market close on Monday, November 7, 2022.

Asymchem and AUM Biosciences jointly announced today the completion of their first GMP production campaign of AUM601.

Day Zero Diagnostics Inc. today announced it was awarded $8.2 million in additional option stage funding from CARB-X, the Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator, a global non-profit partnership dedicated to accelerating early antibacterial research and development to address the rising global threat of drug-resistant bacteria.